Does tirzepatide reduce MACE risk? What the evidence shows

Step 1: understanding what a MACE endpoint actually measures

In cardiovascular outcomes trials, MACE is a composite designed to capture the most clinically significant cardiac events. The three-point MACE definition covers non-fatal heart attack, non-fatal stroke, and death from cardiovascular causes. Regulators require manufacturers of glucose-lowering medicines to demonstrate that a new treatment does not increase cardiovascular risk, what is called non-inferiority. Showing that a treatment actively reduces MACE on top of that is a higher bar and requires a separate, usually longer, trial programme.

Tirzepatide targets two gut-hormone receptors, GIP and GLP-1, both of which have roles in metabolic regulation. Because the GLP-1 pathway is the same one linked to cardiovascular benefit in semaglutide and liraglutide trials, researchers expected tirzepatide to produce a favourable cardiac profile. Whether it translates into a statistically significant MACE reduction is precisely what SURPASS-CVOT was designed to answer. You can read a plain-English overview of tirzepatide's mechanism on the tirzepatide overview page.

Step 2: what SURPASS-CVOT and the broader trial programme found

SURPASS-CVOT enrolled adults with type 2 diabetes at high cardiovascular risk and compared tirzepatide against insulin degludec over a multi-year follow-up. The trial was designed to show non-inferiority on MACE (that tirzepatide did not increase cardiovascular events) and the data reported through 2024 supported that conclusion. Results also pointed to numerically fewer MACE events in the tirzepatide arm compared with the active comparator, though the trial was not powered to confirm superiority on that endpoint.

Separately, the SURMOUNT programme (which studied tirzepatide in adults with obesity rather than diabetes) also collected cardiovascular safety data. SURMOUNT-1, published in the New England Journal of Medicine, showed consistent improvements in cardiometabolic markers including blood pressure, waist circumference and lipid profiles at higher doses, and our page on tirzepatide 30 explains what reaching those higher maintenance doses involves in practice. These are risk-factor improvements, not MACE reductions, an important distinction.

One practical habit worth developing: if you are already on cardiovascular medicines (statins, antihypertensives, antiplatelet agents), check the patient information leaflet for your current drugs before starting any new treatment, it takes less than a minute to flag any interactions to a prescriber before consultation.

Step 3: how this compares with semaglutide's cardiovascular indication

The distinction between tirzepatide and semaglutide on cardiovascular outcomes matters for anyone making an informed treatment choice. Semaglutide (Wegovy) holds a specific UK authorisation for reducing the risk of major cardiovascular events in adults with established cardiovascular disease and obesity, following the SELECT trial. Tirzepatide does not yet hold that specific UK indication. Both medicines are licensed for weight management, and both produce substantial improvements in cardiovascular risk factors. But only semaglutide currently carries the explicit cardiovascular-risk-reduction licence in the UK.

You can explore a detailed side-by-side comparison of the two treatments on the Mounjaro or tirzepatide page. For cost context relevant to choosing between them, the Mounjaro price page sets out what private treatment typically involves. The NICE appraisal of tirzepatide (TA1026) does not yet incorporate a MACE-reduction indication but remains the UK reference point for clinical evidence on tirzepatide in weight management.

Step 4: what this means if you have existing cardiovascular disease

People with a history of heart attack, stroke, heart failure, or established coronary artery disease are not automatically excluded from tirzepatide treatment, but their clinical picture needs careful assessment. Prescribers weigh cardiovascular history alongside other factors (current medications, kidney function, blood pressure control) before recommending any GLP-1 or dual-agonist therapy, and those wondering about physical changes during treatment may find our guide to tirzepatide face useful for setting realistic expectations. Meaningful weight loss itself is associated with improvements in cardiac workload, blood pressure and inflammatory markers, so the benefit-risk calculation is often favourable even without a dedicated MACE licence.

If cardiovascular risk reduction is a primary goal rather than weight management, the conversation with your prescriber will likely centre on whether Wegovy's specific indication is more relevant for your situation, or whether tirzepatide's broader metabolic and weight-loss profile suits you better. That is a clinical decision, not one a checklist can settle. The weight-loss treatment overview explains the licensed options available in the UK. If you have questions before consulting, our tirzepatide l page addresses longer-term use questions alongside the FAQs page, which covers the most common clinical queries our prescribers receive. When you are ready to discuss your own history and goals, check your eligibility with our clinical team.